» Articles » PMID: 32097441

Burden of Disease from Shingles and Post-herpetic Neuralgia in the over 80 Year Olds in the UK

Overview
Journal PLoS One
Date 2020 Feb 26
PMID 32097441
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The current UK vaccination programme for herpes zoster (HZ) excludes people aged ≥80 years. This study aimed to quantify the number of individuals ≥80 years who missed HZ vaccination and the consequent epidemiological and economic burden of HZ and post-herpetic neuralgia (PHN).

Methods: Immunocompetent individuals aged ≥80 years between 1st September 2013 and 31st December 2017 in the Clinical Practice Research Datalink were selected and linked to Hospital Episodes Statistics, where available. Rates of HZ and PHN and healthcare resource utilisation were investigated for the overall study population and by age group (80-84, 85-89, ≥90 years old) and the burden of HZ and PHN was projected to the UK population.

Results: 4,858 HZ episodes and 464 PHN cases were identified in 255,165 individuals over 576,421 person-years (PY). Rates of HZ and PHN were 8.43 (95% confidence interval [CI] 8.19-8.66) and 0.80 (0.73-0.87) per 1,000 PY respectively and lowest in those aged ≥90 (HZ rate 7.37/1,000 PY; PHN rate 0.56/1,000 PY). Within HZ episodes, 10.27% of GP visits, 5.82% of prescribed medications and 21.65% of hospitalisations were related to HZ/PHN. Median length of hospitalisation increased from 7.0 days for all-cause to 10.5 days for HZ/PHN related hospitalisations. Individuals ≥90 stayed in hospital a median of 3-4 days longer than younger groups. Approximately 2.23 million individuals in the UK missed HZ vaccination since 2013 (1.86 million had never been eligible and 365,000 lost eligibility for HZ vaccination), resulting in an estimated 43,149 HZ episodes.

Conclusion: This study highlights the impact of the 80-year upper age limit policy on the health system. Our study estimates that 2.23 million individuals in the UK may have lost the opportunity to be vaccinated and that their burden of HZ and PHN remains high, especially among the very elderly.

Citing Articles

The Incidence of Herpes Zoster Complications: A Systematic Literature Review.

Giannelos N, Curran D, Nguyen C, Kagia C, Vroom N, Vroling H Infect Dis Ther. 2024; 13(7):1461-1486.

PMID: 38896390 PMC: 11219681. DOI: 10.1007/s40121-024-01002-4.


Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol.

Hentzien M, Bonnet F, Bernasconi E, Biver E, Braun D, Munting A BMC Infect Dis. 2024; 24(1):329.

PMID: 38504173 PMC: 10949601. DOI: 10.1186/s12879-024-09192-5.


COVID-19 and herpes zoster: a call to action.

Noushad M, Nassani M, Samran A, Dimashkieh M, Al-Awar M Front Public Health. 2023; 11:1200353.

PMID: 37637810 PMC: 10448515. DOI: 10.3389/fpubh.2023.1200353.


Hospitalization Burden Related to Herpes Zoster Infection in Spain (2016-2019).

Corcuera-Munguia M, Gil-Prieto R, Garcia-Carretero R, Gil-de-Miguel A Infect Dis Ther. 2022; 12(1):143-156.

PMID: 36348228 PMC: 9868224. DOI: 10.1007/s40121-022-00717-6.


Application and Therapeutic Effect of Puncturing of the Costal Transverse Process for Pulsed Radiofrequency Treated T1-T3 Herpes Zoster Neuralgia.

Zhu J, Fei Y, Deng J, Huang B, Yao M J Pain Res. 2020; 13:2519-2527.

PMID: 33116793 PMC: 7548316. DOI: 10.2147/JPR.S266481.

References
1.
Baxter R, Bartlett J, Fireman B, Marks M, Hansen J, Lewis E . Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study. Am J Epidemiol. 2018; 187(1):161-169. PMC: 6018833. DOI: 10.1093/aje/kwx245. View

2.
Kawai K, Gebremeskel B, Acosta C . Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014; 4(6):e004833. PMC: 4067812. DOI: 10.1136/bmjopen-2014-004833. View

3.
WELLER T . Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med. 1983; 309(23):1434-40. DOI: 10.1056/NEJM198312083092306. View

4.
Schmidt-Ott R, Schutter U, Simon J, Poulsen Nautrup B, von Krempelhuber A, Gopala K . Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study. J Infect. 2018; 76(5):475-482. DOI: 10.1016/j.jinf.2018.02.001. View

5.
Matthews I, Lu X, Dawson H, Bricout H, OHanlon H, Yu E . Assessing the effectiveness of zoster vaccine live: A retrospective cohort study using primary care data in the United Kingdom. Vaccine. 2018; 36(46):7105-7111. DOI: 10.1016/j.vaccine.2018.08.037. View